TipRanks on MSN

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer for Renal Impairment Treatment

Alumis Inc. ((ALMS)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...
Healio

‘Strong data’ support ESK-001’s potential as oral treatment for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ESK-001, a tyrosine kinase 2 inhibitor, may be a ...
The Hollywood Reporter

Selma Blair’s First Foray Into Skin Care “Feels Deeply Personal”

The actress, activist and wellness advocate teams with the renowned skin-care brand ESK to design a unique formula for sensitive, mature and reactive skin. By Erin Lassner E-Commerce Writer If you ...
People

Selma Blair Used to Hide Her Inflamed Skin on 'Hard Days.' Now She Has Her Own 'Hero' Skincare Product (Exclusive)

The actress tells PEOPLE that she dealt with problem skin for years due to her autoimmune disease. Then she found answers with skincare brand ESK Hedy Phillips is the Senior Style News Editor at ...
Us Weekly

Selma Blair’s Latest Beauty Partnership With ESK Helps Her Find Her Glow — And Confidence

Selma Blair may be best known for starring in classics like Cruel Intentions and Legally Blonde, but she’s recently added another impressive gig to her résumé. The actress just teamed up with the ...
Nasdaq

Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...
Business Wire

Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that the ...
Nasdaq

Alumis Inc. Reports Positive 52-Week Data for ESK-001, a Next-Generation TYK2 Inhibitor for Moderate-to-Severe Plaque Psoriasis

Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52-week ...